Page 26 - ar2020-21
P. 26

Position Statements







             A position statement is a major documentation and analysis of a broad policy or surveillance issue. Position statements are an
             integral part of CSTE’s work as a member-driven organization, providing programmatic guidance and influencing public health
             on national, state, and local levels. Position statement authors must be active CSTE members.

             Each spring, position statements are submitted to be discussed and voted on by the membership at the Annual Conference in
             June. At the 2021 Virtual CSTE Annual Conference and Business Meeting, the Council ratified three interim position statements
             from 2020 and approved four ordinary process position statements. Below is the list of approved 2021 position statements vetted
             by CSTE membership:

                 • 21-ID-01: Update to the Standardized Surveillance Case Definition and National Notification for 2019 Novel Coronavirus
                 Disease (COVID-19) [superseded Interim-20-ID-02]
                 • 21-ID-02: Revision to the Standardized Case Definition, Case Classification, and Public Health Reporting for Acute Flaccid
                 Myelitis [superseded Interim-20-ID-04]
                 • 21-ID-03: CSTE Recommendations for Modernization of Laws to Prevent HIV Criminalization [superseded Interim-20-ID-05]
                 • 21-ID-04: Update to Public Health Reporting and National Notification of Viral Hemorrhagic Fever (VHF) Caused by Ebola or
                 Marburg Viruses, Old World Arenaviruses (Lassa and Lujo Viruses), New World Arenaviruses (Guanarito, Machupo, Junin,
                 Sabia, and Chapare Viruses), or Crimean-Congo Hemorrhagic Fever Virus
                 • 21-ID-05: Modification of Lyme Disease Case Definition
                 • 21-ID-06: Public Health Reporting and National Notification for Infection Caused by Chlamydia Trachomatis
                 • 21-ID-07: Standardized Case Definition for Alpha-Gal Syndrome








             26       Other Activities
   21   22   23   24   25   26   27   28   29   30   31